His Highness Sheikh Hasher bin Maktoum bin Juma Al Maktoum inaugurates 2023 edition of the PrecisionMed Exhibition & Summit

24 May 2023


PMES 23 opens in Dubai with leading scientists, physicians, policymakers, entrepreneurs, and investors uniting to drive progress in precision medicine in the region Her Excellency Sarah Al Amiri, Minister of State for Public Education and Advanced Technology, explained that key stakeholders in healthcare must “draw on our combined strength to drive further progress in healthcare” PMES 23 takes place 23-24 May 2023 at the Dubai World Trade Centre

His Highness Sheikh Hasher bin Maktoum bin Juma Al Maktoum, Chairman of Dubai Media Incorporated, inaugurated the 2023 edition of the PrecisionMed Exhibition & Summit (PMES) 2023 being held today and tomorrow at the Dubai World Trade Centre. HH Sheikh Hasher bin Maktoum toured the exhibition and summit accompanied by dignitaries.

The Middle East’s leading event dedicated to the advancement of precision medicine offers an important opportunity for key stakeholders, such as regulators, providers, and researchers, to draw work together to drive further progress in healthcare in the region.

In a special recorded message at today’s opening of PMES 23, Her Excellency Sarah Al Amiri – Minister of State for Public Education and Advanced Technology at the Ministry of Industry and Advanced Technology (MoIAT) in the United Arab Emirates, and Secretary-General of the Emirates Genome Council – explained that it was fitting for these stakeholders to gather in the Emirates given its role as a hub for healthcare transformation and advancement.

H.E. Al Amiri stated: “This gathering of scientists, physicians, policymakers, entrepreneurs, and investors is an important part of the evolution of healthcare and medical technology, and it is fitting that the industry is meeting here in the UAE, where technology, innovation and entrepreneurism converge. The last few years have shown just how rapidly medical advances can be made when governments, regulators, businesses, and researchers all move in the same direction. The world demonstrated when we are laser-focused on overcoming a common challenge, we can mobilise resources and capabilities to accelerate innovation and supercharge scientific development. Now – more than ever, we must draw on our combined strength to drive further progress in healthcare.”

Highlighting that the world’s population is set to hit 8.5 billion by 2030, placing even greater strain on public health, H.E. Al Amiri continued: “By investing in transformative healthcare solutions today, we can help create healthier, happier societies, even as populations expand. Precision medicine is one of the critical areas that will change how healthcare systems operate, enhance quality of life, and help achieve the UN’s Sustainable Development Goals.”

H.E. Al Amiri also highlighted the UAE’s National Genome Strategy, launched in March of this year, which aims to develop capabilities and implement genome-based programmes over the next decade.

“The strategy will lead to pioneering precision medicine applications that could transform public health, not only helping to provide the best healthcare and quality of life for people, but also providing significant opportunities for businesses and investors,” H.E. Al Amiri added.

Taking place 23-24 May 2023 at the Dubai World Trade Centre, PMES 23 brings together key figures in healthcare, with talks focusing on the clinical applications of precision medicine in cancer, rare diseases, pharmacogenomics, and stem cell and gene therapies.

The programme also features talks and exhibits on the latest in advanced AI applications in personalised medicine, and how AI and other technological advances in precision medicine are directly helping patients’ journeys.

In his opening remarks, His Excellency Dr. Amin Hussein Al Amiri, Assistant Undersecretary for the Health Regulation Sector at the UAE’s Ministry of Health and Prevention (MoHAP), stated the future of medicine lies in precision medicine. “The medicine currently provided to patients is one treatment approach for various similar diseases. However, this approach may not always succeed in treating patients and could potentially lead to adverse reactions, negatively impacting their health,” said His Excellency.

“The medicine of the future will be highly personalised, taking into account specific patient factors such as their illnesses through the integration of gene therapy and genotype or phenotype analysis using blood tests,” His Excellency added.

Also appearing at the event, Dr. Thekra Hasan Mohamed, Director of Zayed Herbal Complex and Life Sciences Projects, noted that precision medicine is a medical approach that is revolutionizing the way patients are treated. “The UAE has recognised the tremendous potential of precision medicine and has embarked on a journey of integrating this approach into the country's healthcare system. With the launch of the largest genomic study in the region, the Emirati Genome Programme, we aim to focus on using the latest technology and scientific discoveries to analyse genetic data, monitor health status, and provide personalized treatment and care plans for patients," she added.

In his welcome to guests, Dr. Min S Park, Chief Science Officer and Director of Genomic Medicine at Sanimed International Labs and Management – who serves as Chairman of the PMES Scientific Committee – stated: “The opportunity for precision medicine in the Middle East is simply enormous, because it opens completely new preventive measures based on advanced basic research, technology innovation in automation, and AI, allowing the rapid discovery of screening, diagnostics, and treatment options ahead of time.

“Most of all, precision medicine can effectively address the region’s high frequencies of various genetic and non-genetic diseases. Toward achieving the goal, most of the GCC has been heavily investing in national programs, such as the Emirati Genome Program, which will improve the quality of patients’ lives tremendously.”

And finally, Kinjal Zaveri, CEO of One Health, a subsidiary of PureHealth Group – the largest integrated healthcare platform in the region, and Platinum Sponsor of PMES 23 – commented: “Our support of the PrecisionMed Exhibition & Summit reflects our group’s

unwavering commitment to driving transformative change in healthcare. We are proud to be at the forefront of this movement, leveraging our group’s expertise, resources, and capabilities to showcase innovative and personalized healthcare solutions that positively impact patient outcomes and shape the healthcare landscape of tomorrow. We remain committed to contributing to the advancement of precision medicine in the region in line with our vision to unlock time for humankind by ensuring people live longer, fuller and healthier life."

PMES 23 is generously supported by the UAE’s MoIAT, MoHAP, DoH Abu Dhabi, and the Dubai Health Authority (DHA).

PMES 23 & EMERGE 2050

Co-located with PMES is EMERGE 2050, a forum dedicated to innovation and investment in health tech. EMERGE 2050’s mission is to connect technology disruptors at the startup and scale-up stage with the capital and partnering needed to take projects to fruition. The event also aims to address the potential held by digital and telehealth in mitigating the overwhelming costs of incumbent systems. Healthtech presents a significant opportunity to enhance the sustainability of healthcare.

PMES 23, co-located with EMERGE 2050, is supported and sponsored by PureHealth’s entities – including OneHealth, Abu Dhabi Stem Cells Center (ADSCC), and Abu Dhabi Health Services Company (SEHA) – as well as Cleveland Clinic Abu Dhabi, Sheikh Shakhbout Medical City (SSMC), Leader Life Sciences, Thermo Fisher Scientific, and Biorus.

For more information, and to register to attend tomorrow, visit precisionmedexpo.com and emergeghi.com.



Privacy Policy
We have updated our privacy policy. In the latest update it explains what cookies are and how we use them on our site. To learn more about cookies and their benefits, please view our privacy policy. Please be aware that parts of this site will not function correctly if you disable cookies. By continuing to use this site, you consent to our use of cookies in accordance with our privacy policy unless you have disabled them.